ArticleInfectious Disease Modelling2025
Bayesian hierarchical modeling of Mpox in the African region (2022-2024): Addressing zero-inflation and spatial autocorrelation.
Article in Infectious Disease Modelling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox remains a signi_cant public health challenge in endemic regions of Africa. Understanding its spatial distribution and identifying key drivers in high-risk countries is critical for guiding e_ective interventions. This study applies a Zero-Inated Poisson (ZIP) model with spatial autocorrelation to estimate the adjusted relative risk (RR) of Mpox incidence across 24 African countries, strati_ed by Human Development Index (HDI) levels. The model accounts for overdispersion and excess zeros by incorporating spatial random e_ects and socio-environmental covariates, and was validated through model diagnostics and sensitivity analysis, demonstrating robustness of results. Spatial analysis revealed substantial heterogeneity in Mpox incidence, with elevated risk in the Democratic Republic of Congo (DRC), Nigeria, and Central African Republic (CAR) persisting after covariate adjustment (p < 0:001). Higher HDI levels were inversely associated with Mpox risk, with HDI quintile Q4 (very high HDI) showing a signi _cant reduction (aRR = 0.431; 95 % CrI: 0.099{0.724). Protective factors in low-risk areas included increased life expectancy at birth (aRR = 0.768; 95 % CrI: 0.688{0.892), higher educational attainment (aRR = 0.774; 95 % CrI: 0.680{0.921), nonlinear increases in gross national income (GNI) per capita, and a greater density of skilled health workers (aRR = 0.788; 95 % CrI: 0.701{0.934). Conversely, higher urban density was associated with increased Mpox risk, underscoring the inuence of population clustering on transmission dynamics. Notably, statistically signi_cant elevated-risk areas persisted in endemic countries of Western and Central Africa after covariate adjustment (p < 0:001). In contrast, previously undetected risk emerged in parts of Southern and Eastern Africa post-adjustment, revealing latent patterns obscured in the crude analysis (p < 0:001). Exceedance probability maps identi_ed countries with P(RR > 1) > 0.9 as priority areas for intensi_ed surveillance and targeted intervention. These patterns were not fully explained by the included covariates, suggesting the inuence of unmeasured factors such as environmental and climate variability, zoonotic reservoirs, or human{animal interactions. Further research is needed to deepen understanding of Mpox epidemiology and support locally tailored interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.